Innoviva Q3 2023: GSK royalties $57M, net income $82M, launches XACDURO, positive Phase 3 zoliflodacin

Innoviva, Inc.

2023-Q3 EPS reported $1.45 revenue$224,623,000

GSK royalty revenue $57.0M (Q3 2023) vs $65.6M (Q3 2022); net product sales $13.7M.
Net income $82.0M ($1.26 basic EPS) vs $265.5M ($3.81) in Q3 2022; prior year included gain on sale.
Launched XACDURO for Acinetobacter HABP/VABP; announced positive Phase 3 zoliflodacin for gonorrhea.
Appointed Stephen Basso as CFO; repurchased $11.0M of stock in Q3.
Cash $180.0M; invested $25M in Armata Pharmaceuticals.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Innoviva, Inc. reported the third quarter ended September 30, 2023 results: net income $82.0 million, EPS $1.26 basic per share.

Period: the third quarter ended September 30, 2023
Net income: $82.0 million
EPS: $1.26 basic per share
Result: reported results

Exact text from the filing

On November 1, 2023, Innoviva, Inc. (the “Company”) issued a press release regarding its results of operations and financial condition for the quarter ended September 30, 2023.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

Innoviva, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-113410

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.